Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006-2017. by Iyun, Victoria et al.
Accepted author’s manuscript. Published in final edited form as: The Pediatric Infectious Disease 
Journal. 2019 Nov 5. Publisher DOI: https://doi.org/10.1097/INF.0000000000002516  
 
1 
 
Earlier antiretroviral therapy initiation and decreasing mortality among HIV-infected 
infants initiating antiretroviral therapy within 3 months of age in South Africa, 2006-2017 
Victoria Iyun MPH1§, Karl-Gunter Technau MSc2, Brian Eley FCPaed3, Helena Rabie 
MMed[Paed]4, Andrew Boulle PhD1, 5, Geoffrey Fatti MBChB6,7, Matthias Egger FFPH1,8, Frank 
Tanser PhD9, Robin Wood DSC[Med]10, Lee Fairlie FCPaed11, Mark F. Cotton PhD5,13, Mary-
Ann Davies PhD1 
Author Affiliations:   
1. Centre for Infectious Disease Epidemiology and Research, School of Public Health and 
Family Medicine, University of Cape Town Medicine, Cape Town, South Africa 
2. Empilweni Services and Research Centre, Rahima Moosa Mother and Child Hospital, 
University of the Witwatersrand, Johannesburg, South Africa. South Africa. 
3. Red Cross War Memorial Children’s Hospital, Paediatric Infectious Diseases Unit, 
University of Cape Town, Cape Town South Africa. 
4. Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg South 
Africa 
5. Khayelitsha ART Programme and Health Impact Assessment, Western Cape Department 
of Health, Cape Town, South Africa. 
6. Kheth’Impilo, South Africa. 
7. Division of Epidemiology and Biostatistics, Department of Global Health, Faculty of 
Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa 
8. Institute of Social and Preventive Medicine (ISPM), University of Bern, Switzerland  
9. Africa Centre for Population Health, University of Kwazulu Natal, South Africa. 
10. Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa. 
11. Wits Reproductive Health and HIV Research Institute, Faculty of Health Sciences, 
University of the Witwatersrand, Johannesburg, South Africa 
12. Aid for AIDS, Division of Medscheme Holdings Pty Ltd 
 
§Corresponding author:  
Victoria Iyun 
School of Public Health & Family Medicine  
University of Cape Town 
Observatory, Cape Town, 7925 
South Africa 
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
3
5
2
7
9
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Accepted author’s manuscript. Published in final edited form as: The Pediatric Infectious Disease 
Journal. 2019 Nov 5. Publisher DOI: https://doi.org/10.1097/INF.0000000000002516  
 
2 
 
Telephone: +27 745 440417 
Email: Toyiniyun@gmail.com 
 
E-mail addresses of authors: 
 KT: karl-gunter.technau@wits.ac.za  
 BE: brian.eley@uct.ac.za 
 HR: helenarabie@gmail.com 
 AB: andrew.boulle@uct.ac.za 
 GF: geoffrey.fatti@khethimpilo.org 
 ME: matthias.egger@ispm.unibe.ch  
              FT: ftanser@gmail.com 
 RW: robin.wood@hiv-research.org.za 
 LF: lfairlie@wrhi.ac.za 
             MC: mcot@sun.ac.za 
 MD: mary-ann.davies@uct.ac.za  
 
Declaration of interests: We declare that we have no conflicts of interest. 
Funding: Research reported in this publication was supported by the National Institute of 
Allergy and Infectious Diseases of the National Institutes of Health under Award Number 
U01AI069924. The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health. No funding bodies had any role 
in study design, data collection and analysis, decision to publish, or preparation of the 
manuscript. 
Keywords:  infants, early infant antiretroviral therapy, mortality, paediatric HIV, South Africa 
Abbreviated title: Early infant antiretroviral therapy outcomes 
Running head title: Infant antiretroviral therapy outcomes 
 
 
Accepted author’s manuscript. Published in final edited form as: The Pediatric Infectious Disease 
Journal. 2019 Nov 5. Publisher DOI: https://doi.org/10.1097/INF.0000000000002516  
 
3 
 
Abstract  
Introduction: Early infant diagnosis of HIV and antiretroviral therapy (ART) have been rapidly 
scaled-up. We investigated the effect of expanded access to early ART on the characteristics and 
outcomes of infants initiating ART. 
Methods: From nine cohorts within the International epidemiologic Databases to Evaluate AIDS 
- Southern Africa collaboration, we included infants with HIV initiating ART ≤3 months of age 
between 2006-2017. We report ART initiation characteristics and the probability of mortality, 
loss to follow-up (LTFU) and transfer out (TFO) after 6 months on ART, and assessed factors 
associated with  mortality and LTFU. 
Results: A total of 1847 infants started ART at a median age of 60 days (interquartile range 
(IQR) 29-77) and CD4 percentage (%) of 27% (IQR 18%-38%). Across ART initiation periods 
2006-2009 to 2013-2017, ART initiation age decreased from 68 (IQR 53-81) to 45 days (IQR 7-
71) (p<0.001), median CD4% improved from 22% (IQR 15%-34%) to 32% (IQR 22-43) 
(p<0.001) and the proportion with WHO disease stage 3 or 4 declined from 81.6% to 32.7% 
(p<0.001). Overall, 5.0% of infants died, 20.4% became LTFU and 8.5% were TFO six months 
after ART start. Mortality was 10.6% (7.8%-14.4%) in 2006-2009 and 4.6% (3.1%-6.7%) in 
2013-2017 (p<0.001), with similar LTFU across calendar periods (p=0.274). Pre-treatment 
weight-for-age Z-score < -2 was associated with higher mortality.  
Conclusions: HIV-infected infants are starting ART younger and healthier with associated 
declines in mortality. However, the risk of mortality remained undesirably high in recent years. 
Focused interventions are needed to optimize the benefits of earlier diagnosis and treatment. 
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Introduction 
In sub-Saharan Africa, an estimated 140,000 new HIV infections and 73,000 AIDS-related 
deaths occurred in 2018 among children 0-9 years of age.1 Compared to older children, HIV-
infected (HIV+) infants are prone to high early mortality and without ART, 50% will die before 
their second birthday.2 Complexities related to testing, age and weight-related drug changes, 
rifampicin co-treatment of tuberculosis and limited drug formulations make infants a highly 
vulnerable population.  
The World Health Organization’s (WHO) guidelines for paediatric ART initiation has shifted 
from clinical and CD4-based criteria to immediate ART for all (Universal ART). In 2008, 
universal ART was recommended for all HIV+ infants <12 months of age based on findings 
from the landmark Children with HIV Early antiRetroviral (CHER) trial.3, 4  In 2010, South 
Africa adopted universal ART for children under 2 years of age. Furthermore, guidelines for 
lifelong universal ART for all pregnant and breastfeeding women living with HIV (so-called 
“Option B+”) 5 and universal testing for HIV-exposed infants at birth were implemented in 2013 
and 2015, respectively.6 Consequently, by 2017, prevention of mother-to-child transmission of 
HIV (PMTCT) service uptake was >95%, the national coverage of early infant diagnosis (EID) 
and birth HIV testing uptake were both >90%, and paediatric ART coverage was >75%.1, 7  
With expanded ART access, the demographic and clinical characteristics of recently infected 
infants may differ from those infected before the introduction of Option B+ and early testing. 
For example, prematurity, low birth weight (LBW), immunosuppression and comorbidities may 
be more prevalent in those becoming HIV-infected despite widespread coverage of Option B+. 
Of note, infants with these “high risk” characteristics were excluded from the CHER trial 
therefore, the survival benefit may not be generalizable to current programmatic settings, 
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especially in resource-limited settings (RLS) where infants may present for treatment with 
advanced HIV disease.8-10 While the outcomes of infants infected before the availability of EID 
and early ART have been described,10-13 there are limited data on infants initiating early ART 
outside research-controlled settings, in the context of improved EID practices and widespread 
access to ART. Using observational data, we examined temporal trends in the characteristics and 
treatment outcomes of HIV+ infants.  
 
Methods 
Study setting and participants 
We conducted a retrospective cohort study using data from nine IeDEA-SA cohorts in South 
Africa. IeDEA is a global research consortium which collects routine anonymised data on 
patients receiving HIV care and treatment.14 Eight of the nine sites included are mostly in urban 
areas representing primary, secondary and tertiary levels, while one site represents a private 
health sector facility. All sites contributing data to this study have relevant institutional and 
ethical approval. 
We included ART-naïve infants (except for exposure to PMTCT drugs), initiating ART ≤3 
months of age from January 2006 (first WHO treatment guidelines for children) to November 
2017. To better understand the effect of changing WHO eligibility criteria for ART initiation, 
and expansion of PMTCT programmes between 2006 and 2017, infants were grouped according 
to the calendar year of ART initiation: 2006-2009, 2010-2012 and 2013-2017 representing the 
implementation of WHO ART eligibility for all HIV-infected children <2 years in 2010 and 
Option B+ in 2013 respectively. The study entry point was defined as the earliest date of ART 
initiation at the IeDEA-SA clinical site. We defined ART as a combination ≥3 antiretroviral 
drugs from ≥2 different drug classes. The recommended first-line regimen for children <3 years 
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of age prior to 2010 was stavudine, lamivudine and lopinavir/ritonavir (LPV/r). From 2010, 
national treatment guidelines recommended that abacavir replace stavudine in the first-line 
regimen. Guidelines also recommend that newborns receive zidovudine, lamivudine and 
nevirapine for the first month or until >3kg. 
Outcomes and key variable definitions 
Our primary analysis described ART initiation characteristics and outcomes of mortality, loss to 
follow-up (LTFU) and  transfer out (TFO) to other facilities by six, compared across calendar 
periods. We also described weight-for-age z-score (WAZ) improvement in those retained for six 
months after ART initiation. Mortality included all-cause mortality as documented in the 
database. LTFU was defined as not having any documented clinic visit or laboratory result within 
a window period of 4-9 months after ART initiation, irrespective of whether the child returned 
to care >9 months after ART initiation. We further distinguished infants who had no visits after 
the date of ART initiation for up to nine months as having ‘no follow up’ while those with ≥1 
subsequent visit within the first three months on ART but with no visit between 4-9 months after 
ART initiation were classified as ‘LTFU but with subsequent follow up on ART’.15 WAZ 
improvement by 6 months on ART was assessed using the WAZ closest to six months after ART 
start (window 4-9 months). Analysis of outcomes was limited to infants starting ART ≥6 months 
before database closure. Follow-up was right-censored at the earliest of death, last clinic visit 
(for patients LTFU), date of transfer outside the programme or 6 months after ART start. 
WAZ was calculated using the WHO Child Growth Reference Standards.16  We defined 
underweight as WAZ ≤−2 and severely underweight as WAZ ≤−3. Immunosuppression was 
classified using CD4% as severe (<15), moderate (15–24%), or absent (>25%).17 When 
describing weight measurements and laboratory values at ART initiation, we selected the 
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measurement closest to ART start date within a window of -3 weeks to +1 month for WAZ and 
-6 months to +2 weeks after ART start for viral load, CD4 counts and percentages.   
 
Statistical analysis 
We compared ART initiation characteristics across calendar periods using the Chi-square or 
Fisher’s exact test (in the case of sparse data) and Kruskal-Wallis test for categorical and 
continuous variables, respectively. We used Kaplan-Meier methods to estimate the probability 
of mortality, LTFU and TFO and compared survival among various categories using the Log-
rank test. Due to the interdependence of mortality, LTFU and TFO, we also conducted competing 
risks analysis to calculate the cumulative incidence functions for these outcomes. 
We used Cox regression to determine ART initiation characteristics associated with mortality 
and LTFU. Patient-level covariates included in the models were selected a priori as potential 
confounders based on their clinical relevance and data availability and included: age, sex, clinical 
stage, WAZ <-2, log10 viral load, CD4 percentage or immunosuppression level, WHO disease 
stage, PMTCT exposure, year of ART initiation (2006-2009, 2010-2012 and >2013). Adjusted 
Cox regression models were stratified by clinical site to account for heterogeneity.  
We addressed missing baseline data for WAZ, viral load, WHO disease stage and CD4 cell 
counts and percentages using multiple imputation methods. The imputation model relied on the 
assumption of data missing at random and included all ART initiation characteristics, cohort, 
year of ART initiation and outcome variables. We generated 10 imputed dataset and combined 
estimates using Rubin Rules.18 We performed a sensitivity analysis to assess predictors of 
mortality including only patients with complete case data. All statistical analyses were performed 
using STATA 15.0 (STATA Corporation, College Station, TX).  
Accepted author’s manuscript. Published in final edited form as: The Pediatric Infectious Disease 
Journal. 2019 Nov 5. Publisher DOI: https://doi.org/10.1097/INF.0000000000002516  
 
8 
 
 
 
 
 
Results 
ART initiation characteristics 
Between 2006-2017, 17,854 HIV+ children <5 years old initiated ART in the IeDEA-SA sites 
in South Africa (Figure 1). Among these, the proportion starting ART ≤3 months of age increased 
from 6.3% to 20.5% in 2006-09 and 2013-17 respectively (p<0.001).. The median age was 60 
days (IQR: 29-77) and differed substantially by calendar period, ranging from 68 days in 2006-
09 to 45 days in 2013-17 (p <0.001). There was a marked increase in the proportion of infants 
starting treatment within one month of age (vs. 7% [2006-10 ], 14% [2010-13] and 44% [2013-
17]). The median CD4% was 27%, improving from 22% in 2006-09 to 32% in 2013-17 (p 
<0.001).There was a pattern towards an increase in the proportion of females and median log 
viral load over time.  Half of all infants were classified with WHO disease stage three or four, 
however, this proportion decreased substantially over time (81.6% [2006-09] vs. 32.7% [2013-
17]; P<0.001). (Table 1). Compared to infants starting ART in the first month of age (0-30 days), 
those starting between 31-60 days and 61-90 days of age were more likely to be underweight 
(WAZ <-2) (38.5% vs. 60.6% and 60.1%; P<0.001).  
 
Programme outcomes over time 
Among 1692 infants who started ART at least 6 months before individual cohort database closure 
dates, 86 (5.0%) died, 353 (20.8%) became LTFU and 144 (10.2%) were TFO. The 6-month 
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cumulative probabilities of mortality (95% confidence interval [CI]), LTFU and TFO were 6.4% 
(5.2-7.9), 21.5% (19.4-23.3) and 10.6% (9.0-12.3) respectively. Mortality probability was 
highest among infants initiating ART in 2006-09 (10.6% [7.8-14.3]) compared to 2013-2017 
(4.6% [3.1-6.7]), Log-rank test p<0.001). LTFU remained similar across calendar period, 
ranging from 23.8% (20.2-28.0) in 2006-2009 to 21.0% (18.1-24.3) in 2013-2017 (Log-rank test 
p=0.2746). Competing risk analysis yielded similar estimates as shown in Figure 2 and 
Supplementary Table 1. 
The median follow-up time for infants that died was 33 (21-88) days, for LTFU was 0 (0-18) 
days and for TFO was 45 (12-94) days. For 2006-2009 period, death occurred at a median of 27 
(15-57) days versus 45 (21-85) days in the latest period. The median age at death was 94 days 
(IQR: 79-134), with no significant difference across ART initiation time periods (P=0.4655). In 
addition, 61.5% of infants that died initiated treatment between 61-91 days of age. Among those 
LTFU, 74% did not return for a clinic visit after the date of ART initiation for up to 9 months, 
while 26% returned for a subsequent visit after initiating ART (within 3 months on ART) and 
thereafter were LTFU from 3-9 months following ART initiation.  
Risk factors for mortality and LTFU 
Relative to ART start between 2006-2009, the unadjusted mortality hazard ratio (uHR) was lower 
for infants starting ART in 2010-12 (0.47 [0.27-0.79]) and 2013-17 (0.46 [0.28-0.75]) (Table 2), 
however this effect was attenuated after adjusting for disease severity at ART start. Compared 
to having WAZ >-2, infants with WAZ ≤-2 had a 1.7-fold (Adjusted hazard ratio [aHR], 1.74; 
95% CI: 1.07- 2.81) increased risk of death (Table 2). We observed decreasing risk LTFU (i.e. 
no follow-up and LTFU but with subsequent follow-up on ART) over time. Initiating ART 
between 2010-2012 and after 2013 were associated with a decreased unadjusted hazard of LTFU 
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(aHR 0.54, 95% CI: 0.40-0.73 and aHR: 0.46, 95% CI: 0.33-0.62, respectively), compared to 
2006-2009.  
Infants with unknown maternal or infant PMTCT status at ART initiation had a 2.4-fold 
increased risk of being LTFU immediately following the date of ART initiation (no follow up) 
(aHR: 2.43, 95% CI: 1.32-4.59). None of the infant ART initiation characteristics included was 
associated with LTFU after at least one subsequent visit after ART initiation (Supplementary 
Table 2). Overall, similar estimates were identified when complete case analysis was conducted, 
except for no decrease in risk of LTFU in the most recent calendar period (Supplementary Table 
3). 
Weight improvement 
At ART initiation, the median WAZ (IQR) at initiation was -2.4 (-3.7 to -1.1), varying 
significantly across calendar periods (p<0.001), 56% of all infants had WAZ ≤-2 (underweight 
=19.3% plus severely underweight =34.8%). Following 6 months on ART, the median WAZ 
was -1.19 (-2.3 to -0.3) which did not differ by calendar period of ART initiation (p=0.949); 30% 
of infants were underweight.  
 
Discussion 
In this study of infants with HIV starting ART ≤3 months of age, we found that an increasing 
proportion of infants started ART at younger ages and with less advanced HIV disease. Overall, 
mortality was 5.0% with marked differences between the calendar periods. Although mortality 
was halved from 2010 onwards, mortality remained at 4.1% after 2013. An unchanging 
proportion of 1 in 5 infants were LTFU after 6 months of ART, with nearly three-quarters of 
those having no follow-up after their ART initiation visit. Declining mortality is likely mediated 
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by earlier ART initiation reflecting the real-world benefit of the shift to universal ART for infants 
and simultaneous expansion of EID access, particularly birth testing in South Africa.  
Characteristics of children starting ART improved across calendar periods. A marked increase 
in the proportion of infants ≤1 month of age at initiation was a major driver of decreasing age at 
ART start. We attribute this finding to improved EID services and the resulting high coverage of 
>90% in South Africa following introduction of universal birth testing in 2015. However, 
considering the recent context of expanded EID and treatment programmes, infants infected after 
2013 still started ART relatively late at a median age of 45 days. Similar to previous findings, 
we found infant CD4 percentages improved over time 10, 12  
Infants acquiring HIV despite the availability of PMTCT are more likely to be those missed by 
PMTCT programmes, who present for testing when they become sick rather than through routine 
infant follow-up.19 For example, infants initiating ART between 61-90 days old were more likely 
to be underweight than those initiating before 30 days old (57% vs 38%) and underweight infants 
were more likely to die.10, 20 This suggests that older infants are those who missed earlier testing, 
or were infected during the early postpartum period and only present to care with advanced 
disease and hence higher risk of mortality. This partially explains the ongoing burden of 
advanced disease despite high birth testing coverage among those known to the PMTCT 
programme. The national expansion of PMTCT (>95%) was reflected in our study as the 
proportion of infected infants with PMTCT exposure doubled in the latest cohort.  Compared to 
the era of limited access to PMTCT, recent peri-and post-natal transmissions may be occurring 
among an emerging vulnerable population of mothers. These women may have either not 
engaged with the health system or were not virally suppressed despite accessing care due to 
complex social and medical challenges that influence health-seeking behaviour and ART 
adherence.  
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Previous ART implementation studies in infants before expansion of early diagnosis and ART 
for prevention and treatment suggests a trend towards decreasing long-term mortality over time. 
Our findings extends existing evidence to include trends in short-term mortality in infected early-
treated infants.10, 21, 22 The effect of lower mortality over time was not retained after adjusting for 
disease severity, suggesting that lower mortality was mediated by earlier ART initiation and 
improved infant characteristics. The probability of survival for period 2013-2017 was 93%, 
lower than the estimated 6-month survival probability of 97% for all South African infants.23 
The true mortality difference between children with and without HIV is likely even greater due 
to the inherent survival bias in our cohort and our follow-up starting at ART initiation rather than 
birth. An estimated 12-months mortality of 14%has been reported in a cohort of birth-identified 
HIV-infected infants, suggesting significant mortality despite ART in this cohort.24   
The CHER trial enrolled infants starting ART <12 weeks of age (excluding infants with a birth 
weight below 2kg, advanced HIV and CD4 depletion) and followed up for a median of 40 weeks 
comparing early and deferred ART.4 Mortality in our population during the 2013-17 period was 
4.6%, compared to 4.0% reported in the CHER trial arm for immediate ART. Although higher 
mortality rates would be expected in our population,  a shorter follow-up period and high LTFU 
may have masked true mortality. While it is concerning that mortality did not decline further 
during the latest period (compared to 2010-12) when both Option B+ and birth EID were 
implemented, characteristics such as prematurity and associated complications, and infectious 
comorbidities may have contributed to poorer outcomes. Furthermore, since we only measured 
mortality after ART start, it is possible that infants who previously would have died before being 
diagnosed and/or starting ART are now initiating ART earlier, and that pre-ART mortality has 
shifted to mortality after early ART initiation. These explanations are supported by another study 
which reported that 15% more HIV+ infants were lost from the ART programme by one year 
among those who started after 2012 relative to those starting before 2010.25  
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More than half of deaths occurred in the first three months of ART initiation and this pattern was 
most pronounced in the 2006-2009 cohort, similar to earlier studies.26  While high rates of 
bacteraemia and IRIS have been associated with high early mortality, earlier ART start with 
higher CD4 percentages has likely resulted in IRIS becoming less common.27  
The high proportion of infants with no follow up is particularly concerning. Increased mobility 
and poor HIV service retention soon after delivery among women living with HIV are well-
documented and contribute to low retention of infants soon after initiating treatment.28 While 
poor documentation of transfer between health care facilities may underestimate retention, high 
early LTFU may contribute to mortality under-ascertainment. In this respect, although overall 
LTFU didn’t decrease over time, the risk of LTFU after adjustment for disease severity reduced 
in recent years suggesting that true LTFU may be reduced.  Improved focus on retention and 
shift towards individualised care may be more feasible in the context of a decreased overall 
burden of paediatric HIV. As with mortality, it is possible that that pre-ART LTFU has been 
shifted to LTFU on ART following the implementation of birth diagnosis and universal ART.  
To our knowledge, this is the largest study of early infant ART outcomes in sub-Saharan Africa. 
This study includes data from several routine care cohorts representing different levels of health 
care in South Africa. Additionally, the study period covers several guideline periods, allowing 
assessment of the influence of guideline changes while reflecting the realities of routine resource-
limited settings. The routine nature of the settings from which data was collected is evident from 
the amount of missing data and lack of data on PMTCT, maternal socioeconomic factors and 
comorbidities such as tuberculosis may have led to residual confounding. We found an increased 
risk of death among underweight infants but could not assess the extent to which prematurity 
and low birthweight are responsible for low WAZ due to limited data on gestational age at birth. 
There is a chance of survival bias in our selected cohort which may have led to an under-
estimation of mortality.  
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Conclusions 
There have been improvements in infant ART initiation characteristics with related decrease in 
mortality over time. However, early death and LTFU remains unacceptably high. Considering 
the risk of mortality did not decrease further after 2010, there is a need to better understand the 
specific health-care needs of this population of infants who continue to acquire HIV despite 
widespread PMTCT and ART access and uptake.  
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Figure 1: Flow chart describing participant selection and outcomes of infants with HIV initiating 
ART ≤3 months of age from 2006-2017 
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LTFU:                  111 (22.9%) 
TFO:                     66 (13.6%) 
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TFO:                    50 (9.5%) 
 
Died:                  28 (4.1%)                   
LTFU:                138 (20.3%) 
TFO:                   56 (8.2%) 
 
 <6mo minimum follow-up - 155 
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 Table 1. Characteristics of infants who initiated antiretroviral therapy ≤3 months of age across 
South Africa  
PMTCT, Prevention of mother-to-child transmission of HIV; ART, Antiretroviral therapy; 
WAZ, Weight-for-age Z-score; WHO, World Health Organization 
 *P-values were derived from Chi-square and Kruskal-Wallis tests, where appropriate. Values are 
given as number (percentage) or median (interquartile range). #Maternal or infant PMTCT 
exposure 
 
 Characteristics 
 
Overall 
N= 1847 
 
 
2006-2009 
N=483 
 
 
2010-2012 
N=528 
 
 
2013-2017 
N= 836 
 
p 
Age at ART start (days) 60 (29-77) 68 (53-81) 67 (46-80) 45 (7-71) <0.001 
Age category      
    0-30 days 479 (25.9) 34 (7.0) 77 (14.5) 368 (44.0) <0.001 
    31-60 days 464 (25.1) 155 (32.1) 141 (26.7) 168 (20.1)  
    60-90 days 905 (48.9) 294 (60.8) 310 (58.7) 300 (35.8)  
Female 1028 (55.6) 250 (51.8) 317 (60.0) 461 (55.1) <0.031 
CD4 count (cells/µL) 1073 (407-1955) 899 (396-1718) 1274 (487-2028) 1149 (350-2070) <0.035 
CD4 percentage 27 (18-38) 22 (15-33) 26.2 (18-36) 32 (22-43) <0.001 
    CD4% for age <30 days  42 (27-51) 21 (16-28) 38.6 (24-51) 44.3 (31-52)   0.005 
    CD4% for 31-60 days 27 (19-39) 26 (18-38) 26 (16-40) 32 (23-40)   0.053 
    CD4% for 61-90 days  24 (16-33) 21 (14-31) 24 (18.-33) 26 (16-33)   <0.001 
    Missing, N (%) 817 (44) 156 (32) 188 (35) 473 (56)  
Immunosuppression      
    > 25% (none) 556 (54) 143 (43) 177 (51.9) 246 (67.6) <0.001 
    > 15 - ≤ 25% (moderate) 284 (27) 104 (31) 110 (32.3) 70 (19.2)  
    ≤ 15% (severe) 182 (17) 80 (24) 54 (15.8) 48 (13.2)  
     Missing, N (%) 817 (44) 156 (32) 188 (35.6) 473 (56.5)  
Log10 viral load 5.8 (4-6) 5.0 (5-6) 6.0 (5.0-6.6) 5.3 (3.8-6.3) <0.001 
Viral load (copies/ml)      
    <100,000 253 (27.4) 47 (15.4) 63 (22.8) 143 (41.7) <0.001 
    >100,000- 1 Million 282 (30.5) 125 (40.9) 72 (26.1) 85 (24.7)  
    >1 Million 389 (42.1) 133 (43.6) 141 (51.1) 115 (33.5)  
     Missing, N (%) 923 (44.9) 178 (36.8) 252 (47.7) 493 (58.9)  
WHO clinical stage      
    I/II 592 (47.6) 65 (18.4) 152 (45.7) 375 (67.3) <0.001 
    III/IV 652 (52.5) 289 (81.6) 181 (54.6) 182 (32.7)  
     Missing, N (%) 604 (32.7) 129 (26.7) 196 (37.1) 279 (33.3)  
WAZ -2.4 (-3.7 - -1.1) -2.9 (-4.2 - -1.7) -2.3 (-3.6 - -1.0) -1.7 (-3.2 - -0.5) <0.001 
WAZ category        
    <-3  316 (34.8) 146 (43.7) 94 (32.6) 76 (26.6) <0.001 
    - 3 to -2 175 (19.3) 70 (21.1) 62 (21.5) 43 (15.0)  
    >-2 418 (45.9) 118 (35.3) 132 (45.8) 167 (58.3)  
    Missing, N (%) 940 (50.9) 149 (30.8) 241 (45.6) 550 (65.7)  
PMTCT exposure#      
   No  952(51.5) 197 (40.8) 250 (47.3) 505 (60.4) <0.001 
   Yes 233 (12.6) 43 (8.9) 38 (7.2) 152 (18.2)  
   Unknown 662 (35.8) 243 (50.3) 240 (45.5) 179 (21.4)  
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Figure 2. Cumulative incidence functions stratified by calendar period of ART initiation for: 
(A) Mortality accounting for LTFU and TFO as competing events (B) LTFU accounting for 
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death and TFO as competing events. Plot shows time to LTFU defined as no visit from 4-9 
months on treatment. ART, Antiretroviral therapypy; LTFU, Loss to follow-up 
Table 2. Cox proportional hazards model of imputed dataset stratified by cohort: Infant 
characteristics associated with mortality and loss to follow-up within the first 6 months on 
ART (n=1692) 
 Mortality  Loss to follow-up  
 Crude HR  
(95% CI) 
Adjusted HR  
(95% CI) 
 Crude HR  
(95% CI) 
Adjusted HR  
(95% CI) 
 
Age in weeks 1.47 (0.89-2.45) 0.95 (0.53-1.71)  0.93 (0.74-1.17) 0.89 (0.68-1.15)  
Female 0.68 (0.44-1.02) 0.70 (0.46-1.07)  0.89 (0.72-1.09) 0.88 (0.71-1.09)  
ART initiation year       
    2006-2009 Ref   Ref   
    2010-2012 0.47 (0.27-0.79) 0.76 (0.42-1.36)  0.77 (0.59-1.01) 0.54 (0.40-0.73)  
    2013-2017 0.46 (0.28-0.75) 0.98 (0.54-1.75)  0.80 (0.62-1.03) 0.46 (0.33-0.62)  
WHO disease stage       
    I/II Ref   Ref   
    III/IV 1.85 (1.14-2.99) 1.08 (0.61-1.91)  0.87 (0.65-1.14) 0.91 (0.65-1.28)  
CD4 percentage 0.98 (0.96-0.99) 0.98 (0.96-1.00)  0.99 (0.98-1.00) 1.00 (0.99-1.01)  
WAZ       
    >-2 Ref   Ref   
    ≤-2 2.43 (1.53-3.84) 1.74 (1.07-2.81)  0.93 (0.70-1.23) 0.95 (0.71-1.26)  
Log viral load 1.38 (1.07-1.58) 1.14 (0.89-1.46)  0.97 (0.88-1.08) 1.02 (0.92-1.13)  
PMTCT exposure       
    No Ref   Ref   
    Yes 1.17 (0.74-1.85) 0.87 (0.50-1.49)  0.59 (0.46-0.77) 1.05 (0.61-1.69)  
    Unknown 1.10 (0.62-1.97) 1.20 (0.50-2.86)  0.83 (0.62-1.11) 1.08 (0.65-1.78)  
CI, confidence interval; HR, hazard ratio; WAZ, weight-for-age z-score; WHO 
*Status of infant exposure to maternal or infant PMTCT  
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